http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021069227-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9baf3defa9dc998356da178a79d4920 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate | 2018-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83f3f518ad298e252650607a449cf2f2 |
| publicationDate | 2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021069227-A1 |
| titleOfInvention | A3 adenosine receptor ligand for managing cytokine release syndrome |
| abstract | Provided is a method of managing cytokine release syndrome (CRS) in a subject undergoing immunotherapy treatment, the method includes administering to the subject an amount of an A3 adenosine receptor (A3AR) ligand effective to manage one or more of (i) level of at least one inflammatory cytokine and (ii) at least one CRS symptom; wherein the management is without significantly affecting the immunotherapy treatment. Also provided is an A3AR ligand and a composition including the ligand for use in the management of cytokine release syndrome (CRS) in a subject undergoing immunotherapy treatment, the management includes one or more of (i) managing level of at least one inflammatory cytokine and (ii) managing at least one CRS symptom; wherein the management is without significantly affecting the immunotherapy treatment. |
| priorityDate | 2017-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 353.